Kedrion Biopharma has expanded the distribution network for Ryplazim, a plasma-derived human plasminogen, specifically for patients with plasminogen deficiency type 1 (PLGD-1) in the US.
The expansion ensures timely access to the only US Food and Drug Administration (FDA)-approved therapy for PLGD-1, a serious condition causing abnormal fibrin-rich lesions.
The lesions may potentially lead to vision and hearing loss, airway obstruction, and infertility.
Kedrion expanded its distribution network based on the recent FDA approval for technology transfer and capacity expansion of Ryplazim.
The expansion includes a new distribution partner and two new speciality pharmacies, significantly increasing the availability of this vital treatment for more patients.
Kedrion Biopharma global business and US general manager CCO Bob Rossilli said: “The FDA’s approval of the tech transfer and capacity expansion enables us to manufacture greater volumes of Ryplazim.
“We are focused on educating healthcare providers on identifying and diagnosing PLGD-1 patients. Once diagnosed, a strong infrastructure is essential to ensure timely product delivery and an improvement in care for patients.
“Our goal is to ensure that every patient has reliable access to therapy they may need for the rest of their life. This distribution network is a significant step toward making that goal a reality.”
CuraScript SD has joined existing partners, FFF Enterprises and The Alliance Pharmacy, in distributing Ryplazim to PLGD-1 patients.
In addition, CVS Health and Soleo Health have been added to the list of specialty pharmacies carrying Ryplazim, alongside Nufactor, to ensure wider availability.
Kedrion said that its collaborative effort underscores its commitment to improving patient care and expanding access to essential therapies.
The enhanced distribution network ensures that patients diagnosed with PLGD-1 can receive treatment promptly and effectively, said the Italy-based biopharma company.
